Kamada slides on AAT miss, still planning MAA submission

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) fell $4.74 (34%) to $9.08 in New York on Friday after reporting that twice-daily aerosolized alpha-1 antitrypsin (AAT) missed the primary endpoint in a 168-patient Phase II/III trial to treat AAT deficiency. The company's inhaled AAT did not improve time to first moderate or severe exacerbation at one year vs. placebo. The Tel Aviv Stock Exchange is closed Fridays. ...